The BCL10 gene, located on chromosome 1, is documented in association with MALT lymphoma in the gene and chromosome location data of this packet. Gastric MALT lymphoma is linked to Helicobacter pylori infection, as stated in the packet definition. No Mendelian inheritance pattern is listed in this packet. Somatic variant data from ClinVar are not present in this packet; the known_genes_with_validity entry for BCL10 is documented without an assigned ClinGen evidence classification in the available data.

Diagnosis is based on histopathological evaluation of biopsy specimens demonstrating the characteristic small B-lymphocyte morphology described in the packet definition. The condition is classified as an extranodal lymphoma arising in mucosa-associated lymphoid tissue. The packet definition references H. pylori infection as relevant to gastric cases; testing for this pathogen is associated with gastric presentations in the documented literature context. Specific diagnostic criteria, approved companion diagnostics, and standardized staging protocols are not enumerated in the fields available in this packet.

Lenalidomide (Revlimid) is documented in the approved_treatments field with FDA NDA status and an active market status. Within the FDA orphan drug program, three additional agents carry APPROVED designation specifically for extranodal marginal zone lymphoma or MALT lymphoma: lisocabtagene maraleucel (Breyanzi), umbralisib (Ukoniq), and zanubrutinib (Brukinsa), as recorded in the orphan_drugs field. Multiple additional agents—including axicabtagene ciloleucel, idelalisib, odronextamab, parsaclisib, and tafasitamab-cxix—hold orphan designation status for this condition. Several agents listed in the orphan_drugs field carry WITHDRAWN status for MALT-related indications, including copanlisib and ublituximab. Ten clinical trials are documented in this packet as active or recruiting.

MALT lymphoma is described in the packet definition as an indolent malignancy, indicating a slow-growing natural history relative to other non-Hodgkin lymphoma subtypes. Specific survival statistics, response rates, and long-term outcome data are not present in this packet. The condition involves blood and immune, endocrine, and respiratory organ systems, with clinical trajectory reflecting the site and extent of mucosal involvement. No natural history field data are included in this packet.

Ten clinical trials involving MALT lymphoma or closely related extranodal marginal zone lymphoma are recorded in this packet. Documented examples include a Phase 1 investigation of 19(T2)28z1xx CAR T cells at Memorial Sloan Kettering Cancer Center (NCT04464200, active not recruiting, projected completion 2027) and a Phase 1 study of BGB-16673, a BTK-targeted protein degrader, conducted by BeiGene (NCT05294731, recruiting, projected completion 2029). Multiple agents at the designated stage—axicabtagene ciloleucel, idelalisib, odronextamab, parsaclisib, and tafasitamab-cxix—reflect sustained investigational interest in this disease.